The treatment landscape of Ph+ ALL has been reshaped over the past two decades with the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs), resulting in dramatic improvements in long-term survival [1,2]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.